Article

Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of ARX788 in the I-SPY 2.2 Phase 2 Adaptive Clinical Trial for Breast Cancer

05/04/2022

Excerpt from the Press Release: Quantum Leap Healthcare Collaborative™ (Quantum Leap) and Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the selection of Ambrx’s antibody drug conjugate (ADC) ARX788 for a new investigational treatment arm in the I-SPY 2.2…

Read More

DCN Dx Acquires Microbiological Testing Products Company Biomed Diagnostics

05/04/2022

Excerpt from the Press Release: CARLSBAD, Calif., April 25, 2022 /PRNewswire/ — DCN Dx, a global leader in the end-to-end development, manufacture, and commercialization of point-of-use tests, today announced it has completed its acquisition of Biomed Diagnostics, Inc., a microbiological testing products company based in White City, Oregon. The acquisition expands DCN Dx’s footprint in the point-of-use testing…

Read More

Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis

05/04/2022

– Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD)– AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class profile– Achieved clinically meaningful responses in stool frequency and histologic healing in both 3mg and 10mg dosage groups– Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 in chronic…

Read More

EpicentRx “BETA-PRIME” Phase 1 Study Progresses After Demonstrating Good Safety and Tolerability

05/02/2022

Phase 1 trial with cancer-targeting adenovirus enhanced with a TGFβ Trap continues to investigate safety and anti-tumor activity in patients with advanced cancer Excerpt from the Press Release: TORREY PINES, Calif., April 21, 2022 /PRNewswire/ — EpicentRx Inc., a leading-edge immunotherapy company using groundbreaking science to treat cancer and multiple inflammatory-driven diseases, today announced the initiation of the…

Read More

MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research

05/02/2022

Excerpt from the Press Release: LA JOLLA, Calif., April 20, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced data demonstrating that MN-166 (ibudilast) prevents metastasis in a uveal melanoma (UM) animal model was…

Read More

NuVasive Simplify Cervical Disc Two-level Data Published in Journal of Neurosurgery: Spine

05/02/2022

Peer-reviewed results from the two-level multi-center FDA Investigational Device Exemption study reiterate disc’s superiority to ACDF Excerpt from the Press Release: SAN DIEGO, April 21, 2022 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the NuVasive Simplify® Cervical Disc (Simplify Disc) two-level U.S. Food…

Read More

Truvian Sciences Appoints Top Industry Veterans to its Leadership Team as it Prepares to Commercialize its Automated Benchtop Blood Testing System

04/29/2022

— Executive appointments position the company for continued growth and expansion — Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Truvian Sciences (“Truvian”) today announced four executive appointments that bring expanded industry and commercialization experience to the company as it advances toward submitting for U.S. Food and Drug Administration (FDA) clearance of its automated benchtop blood testing…

Read More

EVUSHELD™ significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations

04/29/2022

Pre-exposure prophylaxis (prevention) trial reduced risk of symptomatic COVID-19, with no severe disease or COVID-19-related deaths in EVUSHELD group Data published in the New England Journal of Medicine Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s EVUSHELD™(tixagevimab and cilgavimab), formerly AZD7442, reduced…

Read More

BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey

04/29/2022

Excerpt from the Press Release: HOPEWELL, N.J. & CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, and Crossroads4Hope, A Network of Cancer Support, a 501(c)(3) organization committed to transforming the cancer experience for patients and their families…

Read More

Purigen Launches Ionic® Cells to Pure DNA Kit for White Blood Cell and Peripheral Blood Mononuclear Cell Control Samples

04/28/2022

New kit enhances menu of FFPE solutions and allows oncology researchers to extract higher yields of concentrated DNA compared to traditional techniques Excerpt from the Press Release: PLEASANTON, Calif.–(BUSINESS WIRE)–Purigen Biosystems, Inc., a leading provider of next-generation technologies for extracting and purifying nucleic acids from biological samples, today announced the launch of the Ionic Cells…

Read More